Pasar al contenido principal

MODULACION DE LA AUTOFAGIA COMO TRATAMIENTO CONTRA LA OBESIDAD DERIVADA DE CILIOPATIAS

PID2019-108827RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis

  • Corral Nieto, Yaiza
  • Fernández Pereira, Amanda Gabrielly
  • Ventura-San Pedro, Laura
  • Paredes, Sonia Belén
  • Pérez-Cobas, Ana Elena
  • Perez-Lanzon, María
  • Durand, Sylvere
  • Moreno-Cruz, Paula
  • Manrique, Laura
  • Benítez-Fernández, Rocío
  • Leal Lassalle, Héctor
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Alechaga, Élida
  • Pozo, Oscar J.
  • Boya, Patricia
  • Fuentes, José Manuel
  • Sica, Valentina
  • Kroemer, Guido
  • Bravo-San Pedro, José Manuel
Ciliopathies are genetic disorders characterized by defective primary cilia function, with obesity as a clinical manifestation in certain cases, including Alström syndrome, which is caused by ALMS1 mutations. The link between cilia and lipid metabolism remains poorly understood, but evidence suggests a role for impaired autophagy. Autophagy affects both intra- and extracellular levels of ACBP, which can act as an obesogenic factor. Our multi-omics study reveals early hepatic dyslipidemia, impaired autophagy, and hepatic accumulation of ACBP in presymptomatic male mice lacking Alms1 gene. These conditions are consistent with the obesogenic phenotype and with alterations in the gut microbiota that manifest as the mice age and develop obesity. Importantly, reducing excessive ACBP with a neutralizing monoclonal antibody limits weight gain and metabolic defects in Alms1-/- mice in an autophagy-independent manner. Altogether, the data support the idea that ciliopathy-associated obesity, particularly Alström syndrome, may be mitigated by ACBP neutralization., J.M.B.-S.P. was funded by MICIU/AEI/10.13039/501100011033 and by ESF Investing in your future (Ramón y Cajal Program, RYC-2018-025099-I). This work has been supported by the following grants: PID2019-108827RA-I00 funded by MICIU/AEI/10.13039/501100011033; PDC2022-133398-I00 funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. JMF was funded by the Instituto de Salud Carlos III, CIBERNED, grant number CB06/05/0041. YCN was funded by the Community of Madrid (CT5/21/PEJ-2020-TL/BMD-17685) and PDC2022-133398-I00 contract. AGFP was supported by RYC-2018-025099-I contract. AEP-C is funded by a Grant for the Attraction of Talent within the Community of Madrid (2019-T2/BMD-12874). L.V.-S.P. is funded by Barcelona Supercomputing Center (BSC). P.M.-C. was funded by the MINECO Spanish Ministry (FPI grant, PRE2020-092668). L.M. was funded by the INVESTIGO program (CAM, 09-PIN1-00009.8/2022). The authors thank Drs. Victoria Cachofeiro and Ernesto Martinez-Martinez for the support in the conceptualization and execution of this work; UCM animal facility for the daily care and control of the mice used in this study, especially to Susana and María Pilar Bringas de la Lastra; to Ana Romero Miranda, Beatriz Delgado García and Raquel Rodrigues Diez for helpful assistance with tissue evaluation; to Erwan Boëdec as responsible technique of plateforme Biochimie et Biophysique, Institut de Psychiatrie et Neurosciences de Paris (IPNP)/UMR_S1266 for the production of recombinant ACBP protein; to Dr. Laura Clavaín and EGO GENOMICS S.L. for the metabolomic statistical analysis; to the Facility of Innovation and Analysis in Animal Source Foodstuffs (SiPA) of SAIUEx of the University of Extremadura for carrying out proteomic analysis; and Dreamgenics for performing the experiments and bioinformatic analysis of RNAseq data. We thank the Translational Genomics Unit (NGS) of the Ramón y Cajal Institute for Health Research (IRYCIS) for performing the microbiota sequencing and preliminary analysis. We also thank Dr. Christopher C. Goodnow for kindly providing the Alms1-/- mouse model.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Changes in Liver Lipidomic Profile in G2019S- LRRK2 Mouse Model of Parkinson's Disease

  • Corral Nieto, Yaiza
  • Yakhine-Diop, Sokhna M. S.
  • Moreno-Cruz, Paula
  • Manrique García, Laura
  • Gabrielly Pereira, Amanda
  • Morales-García, José A.
  • Niso-Santano, Mireia
  • González-Polo, Rosa A.
  • Uribe-Carretero, Elisabet
  • Durand, Sylvère
  • Maiuri, Maria Chiara
  • Paredes-Barquero, Marta
  • Alegre-Cortés, Eva
  • Canales-Cortés, Saray
  • López de Munain, Adolfo
  • Pérez-Tur, Jordi
  • Pérez-Castillo, Ana
  • Kroemer, Guido
  • Fuentes, José M.
  • Bravo-San-Pedro, José Manuel
15 páginas, 4 figuras, The identification of Parkinson's disease (PD) biomarkers has become a main goal for the diagnosis of this neurodegenerative disorder. PD has not only been intrinsically related to neurological problems, but also to a series of alterations in peripheral metabolism. The purpose of this study was to identify metabolic changes in the liver in mouse models of PD with the scope of finding new peripheral biomarkers for PD diagnosis. To achieve this goal, we used mass spectrometry technology to determine the complete metabolomic profile of liver and striatal tissue samples from WT mice, 6-hydroxydopamine-treated mice (idiopathic model) and mice affected by the G2019S-LRRK2 mutation in LRRK2/PARK8 gene (genetic model). This analysis revealed that the metabolism of carbohydrates, nucleotides and nucleosides was similarly altered in the liver from the two PD mouse models. However, long-chain fatty acids, phosphatidylcholine and other related lipid metabolites were only altered in hepatocytes from G2019S-LRRK2 mice. In summary, these results reveal specific differences, mainly in lipid metabolism, between idiopathic and genetic PD models in peripheral tissues and open up new possibilities to better understand the etiology of this neurological disorder., This research was supported by “Instituto de Salud Carlos III”, “Fondo de Investigaciones Sanitarias” (PI15/0034), “CIBERNED-ISCIII” (CB06/05/0041 and 2015/03), and partially supported by “European Regional Development Fund (ERDF)” from the European Union. J.M.B.-S.P. is funded by “Ramon y Cajal Program” (RYC-2018-025099-I) and supported by Spain’s Ministerio de Ciencia e Innovación (PID2019-108827RA-I00). Y.C.N. and L.M.G. are funded by Community of Madrid (CT5/21/PEJ-2020-TL/BMD-17685 and CT36/22-41-UCM-INV respectively). S.M.S.Y.-D. was supported by CIBERNED-ISCIII. P.M.-C. is funded by the MINECO Spanish Ministry (FPI grant, PRE2020-092668). M.N.-S. was funded by “Ramon y Cajal Program” (RYC-2016-20883). E.U.-C. and S.C.-C. were supported by an FPU predoctoral fellowship (FPU16/00684) and FPU19/04435), respectively, from “Ministerio de Educación, Cultura y Deporte”. M.P-B was funded by a University of Extremadura fellowship. E.A-C was supported by a Grant (IB18048) from Junta de Extremadura, Spain. J.M.F. received research support from the “Instituto de Salud Carlos III”; “Fondo de Investigaciones Sanitarias” (PI15/0034) and CIBERNED-ISCIII (CB06/05/0041 and 2015/03). A.P.-C. was supported by MINECO (SAF2014-52940-R and SAF2017-85199-P). J.P.-T. received funding from CIBERNED-ISCIII (CB06/05/1123 and 2015/03). G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)—Projets blancs; ANR under the frame of E-Rare-2, the ERANet for Research on Rare Diseases; AMMICa US/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Le Cancer du Sein, Parlons-en!”; Cancéropôle Ile de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis

  • Corral Nieto, Yaiza
  • Fernández Pereira, Amanda Gabrielly
  • Ventura-San Pedro, Laura
  • Paredes, Sonia Belén
  • Pérez-Cobas, Ana Elena
  • Perez-Lanzon, María
  • Durand, Sylvere
  • Moreno-Cruz, Paula
  • Manrique, Laura
  • Benítez-Fernández, Rocío
  • Leal Lassalle, Héctor
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Alechaga, Élida
  • Pozo, Oscar J.
  • Boya, Patricia
  • Fuentes, José Manuel
  • Sica, Valentina
  • Kroemer, Guido
  • Bravo-San Pedro, José Manuel
Ciliopathies are genetic disorders characterized by defective primary cilia function, with obesity as a clinical manifestation in certain cases, including Alström syndrome, which is caused by ALMS1 mutations. The link between cilia and lipid metabolism remains poorly understood, but evidence suggests a role for impaired autophagy. Autophagy affects both intra- and extracellular levels of ACBP, which can act as an obesogenic factor. Our multi-omics study reveals early hepatic dyslipidemia, impaired autophagy, and hepatic accumulation of ACBP in presymptomatic male mice lacking Alms1 gene. These conditions are consistent with the obesogenic phenotype and with alterations in the gut microbiota that manifest as the mice age and develop obesity. Importantly, reducing excessive ACBP with a neutralizing monoclonal antibody limits weight gain and metabolic defects in Alms1-/- mice in an autophagy-independent manner. Altogether, the data support the idea that ciliopathy-associated obesity, particularly Alström syndrome, may be mitigated by ACBP neutralization., J.M.B.-S.P. was funded by MICIU/AEI/10.13039/501100011033 and by ESF Investing in your future (Ramón y Cajal Program, RYC-2018-025099-I). This work has been supported by the following grants: PID2019-108827RA-I00 funded by MICIU/AEI/10.13039/501100011033; PDC2022-133398-I00 funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. JMF was funded by the Instituto de Salud Carlos III, CIBERNED, grant number CB06/05/0041. YCN was funded by the Community of Madrid (CT5/21/PEJ-2020-TL/BMD-17685) and PDC2022-133398-I00 contract. AGFP was supported by RYC-2018-025099-I contract. AEP-C is funded by a Grant for the Attraction of Talent within the Community of Madrid (2019-T2/BMD-12874). L.V.-S.P. is funded by Barcelona Supercomputing Center (BSC). P.M.-C. was funded by the MINECO Spanish Ministry (FPI grant, PRE2020-092668). L.M. was funded by the INVESTIGO program (CAM, 09-PIN1-00009.8/2022). The authors thank Drs. Victoria Cachofeiro and Ernesto Martinez-Martinez for the support in the conceptualization and execution of this work; UCM animal facility for the daily care and control of the mice used in this study, especially to Susana and María Pilar Bringas de la Lastra; to Ana Romero Miranda, Beatriz Delgado García and Raquel Rodrigues Diez for helpful assistance with tissue evaluation; to Erwan Boëdec as responsible technique of plateforme Biochimie et Biophysique, Institut de Psychiatrie et Neurosciences de Paris (IPNP)/UMR_S1266 for the production of recombinant ACBP protein; to Dr. Laura Clavaín and EGO GENOMICS S.L. for the metabolomic statistical analysis; to the Facility of Innovation and Analysis in Animal Source Foodstuffs (SiPA) of SAIUEx of the University of Extremadura for carrying out proteomic analysis; and Dreamgenics for performing the experiments and bioinformatic analysis of RNAseq data. We thank the Translational Genomics Unit (NGS) of the Ramón y Cajal Institute for Health Research (IRYCIS) for performing the microbiota sequencing and preliminary analysis. We also thank Dr. Christopher C. Goodnow for kindly providing the Alms1-/- mouse model.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Neutralization of DBI/ACBP for the prevention of ciliopathy-associated obesity

  • Corral Nieto, Yaiza
  • Guido Kroemer
  • Bravo San Pedro, José Manuel
Obesity is a feature of only a subset of ciliopathies, including Alström syndrome, a rare genetic disorder caused by ALMS1 deficiency. In our recent work, we applied integrative multi-omics network analysis to one of these ciliopathies that develop with obesity, the Alms1-deficient mouse model andidentified DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) as a central driver of ciliopathy-associated obesity. We found that ALMS1 deficiency induces early hepatic dyslipidemia accompanied by impaired macroautophagy/autophagy and pathological accumulation of DBI/ACBP,preceding overt obesity. Importantly, prophylactic DBI/ACBP neutralization with monoclonal antibodies prevents weight gain and metabolic alterations without restoring autophagic markers,indicating that DBI/ACBP acts as an obesogenic effector downstream of, or parallel to, defective autophagy. These findings position DBI/ACBP as a metabolically relevant autophagy-associated regulator in ciliopathy and suggest that therapeutic benefit can be achieved by targeting autophagy-linked effectors without directly correcting autophagic flux. This punctum discusses our results in the context of hepatic autophagy and lipid metabolism, highlighting DBI/ACBP as a mechanistic link between ciliary dysfunction, altered autophagy, and metabolic disease